Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib
- Author
- GOLDBERG, Stuart L1 ; LEI CHEN2 ; GUERIN, Annie3 ; MACALALAD, Alexander R3 ; NATHAN LIU3 ; KAMINSKY, Michael3 ; ERICSON, Solveig G2 ; WU, Eric Q3
[1] John Theurer Cancer Center at Hackensack University, Medical Center, Hackensack, NJ, United States
[2] Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
[3] Analysis Group Inc, Boston, MA, United States - Source
Current medical research and opinion. 2013, Vol 29, Num 9, pp 1075-1082, 8 p ; ref : 20 ref
- ISSN
- 0300-7995
- Scientific domain
- General medicine general surgery; Pharmacology drugs
- Publisher
- Informa, Colchester
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- Chronic myelogenous leukemia Progression-free survival Quantitative real time polymerase chain reaction Tyrosine kinase inhibitor
- Keyword (fr)
- Analyse quantitative Anticancéreux Homme Imatinib Inhibiteur de la tyrosine kinase Inhibiteur enzyme Leucémie myéloïde chronique Long terme Pronostic Protein-tyrosine kinase Réaction chaîne polymérase Surveillance Temps réel Traitement de première intention Survie sans progression Biologie moléculaire Cancer Enzyme Hémopathie maligne Syndrome myéloprolifératif Transferases
- Keyword (en)
- Quantitative analysis Antineoplastic agent Human Imatinib Tyrosine kinase inhibitor Enzyme inhibitor Chronic myelogenous leukemia Long term Prognosis Protein-tyrosine kinase Polymerase chain reaction Surveillance Real time First line treatment Progression free survival Molecular biology Cancer Enzyme Malignant hemopathy Myeloproliferative syndrome Transferases
- Keyword (es)
- Análisis cuantitativo Anticanceroso Hombre Imatinib Inhibidor tyrosine kinase Inhibidor enzima Leucemia mieloidea crónica Largo plazo Pronóstico Protein-tyrosine kinase Reacción cadena polimerasa Vigilancia Tiempo real Tratamiento de primera línea Supervivencia sin progresión Biología molecular Cáncer Enzima Hemopatía maligna Mieloproliferativo síndrome Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27719878
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1185/03007995.2013.812034 
https://dx.doi.org/10.1185/03007995.2013.812034
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1185\/03007995.2013.812034\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:137:\"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Current medical research and opinion\";s:9:\"\u0000*\u0000stitle\";s:20:\"Curr. med. res. opin\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1075\";s:8:\"\u0000*\u0000epage\";s:4:\"1082\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0300-7995\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GOLDBERG\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Stuart L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:8:\"LEI CHEN\";i:1;s:13:\"GUERIN, Annie\";i:2;s:22:\"MACALALAD, Alexander R\";i:3;s:10:\"NATHAN LIU\";i:4;s:17:\"KAMINSKY, Michael\";i:5;s:18:\"ERICSON, Solveig G\";i:6;s:10:\"WU, Eric Q\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:137:\"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib\";s:8:\"\u0000*\u0000place\";s:10:\"Colchester\";s:6:\"\u0000*\u0000pub\";s:7:\"Informa\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1185\/03007995.2013.812034\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:137:\"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Current medical research and opinion\";s:9:\"\u0000*\u0000stitle\";s:20:\"Curr. med. res. opin\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1075\";s:8:\"\u0000*\u0000epage\";s:4:\"1082\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0300-7995\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GOLDBERG\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Stuart L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:8:\"LEI CHEN\";i:1;s:13:\"GUERIN, Annie\";i:2;s:22:\"MACALALAD, Alexander R\";i:3;s:10:\"NATHAN LIU\";i:4;s:17:\"KAMINSKY, Michael\";i:5;s:18:\"ERICSON, Solveig G\";i:6;s:10:\"WU, Eric Q\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:137:\"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib\";s:8:\"\u0000*\u0000place\";s:10:\"Colchester\";s:6:\"\u0000*\u0000pub\";s:7:\"Informa\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:28:\"10.1185\/03007995.2013.812034\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1185\/03007995.2013.812034\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:137:\"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Current medical research and opinion\";s:9:\"\u0000*\u0000stitle\";s:20:\"Curr. med. res. opin\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1075\";s:8:\"\u0000*\u0000epage\";s:4:\"1082\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0300-7995\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GOLDBERG\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Stuart L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:8:\"LEI CHEN\";i:1;s:13:\"GUERIN, Annie\";i:2;s:22:\"MACALALAD, Alexander R\";i:3;s:10:\"NATHAN LIU\";i:4;s:17:\"KAMINSKY, Michael\";i:5;s:18:\"ERICSON, Solveig G\";i:6;s:10:\"WU, Eric Q\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:137:\"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib\";s:8:\"\u0000*\u0000place\";s:10:\"Colchester\";s:6:\"\u0000*\u0000pub\";s:7:\"Informa\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1185\/03007995.2013.812034\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:137:\"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Current medical research and opinion\";s:9:\"\u0000*\u0000stitle\";s:20:\"Curr. med. res. opin\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1075\";s:8:\"\u0000*\u0000epage\";s:4:\"1082\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0300-7995\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GOLDBERG\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Stuart L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:8:\"LEI CHEN\";i:1;s:13:\"GUERIN, Annie\";i:2;s:22:\"MACALALAD, Alexander R\";i:3;s:10:\"NATHAN LIU\";i:4;s:17:\"KAMINSKY, Michael\";i:5;s:18:\"ERICSON, Solveig G\";i:6;s:10:\"WU, Eric Q\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:137:\"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib\";s:8:\"\u0000*\u0000place\";s:10:\"Colchester\";s:6:\"\u0000*\u0000pub\";s:7:\"Informa\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1185\/03007995.2013.812034\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:137:\"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Current medical research and opinion\";s:9:\"\u0000*\u0000stitle\";s:20:\"Curr. med. res. opin\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1075\";s:8:\"\u0000*\u0000epage\";s:4:\"1082\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0300-7995\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GOLDBERG\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Stuart L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:8:\"LEI CHEN\";i:1;s:13:\"GUERIN, Annie\";i:2;s:22:\"MACALALAD, Alexander R\";i:3;s:10:\"NATHAN LIU\";i:4;s:17:\"KAMINSKY, Michael\";i:5;s:18:\"ERICSON, Solveig G\";i:6;s:10:\"WU, Eric Q\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:137:\"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib\";s:8:\"\u0000*\u0000place\";s:10:\"Colchester\";s:6:\"\u0000*\u0000pub\";s:7:\"Informa\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
